Results 81 to 90 of about 24,684 (197)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration

Journal of International Medical Research, 2020
Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration.
Hai-Tao Pan, Jun-Jun Wang, Jun-Long Huang, Yuan-Lu Shuai, Jia Li, Zi-Zhong Hu, Yu-Zhi Ding, Qing-Huai Liu   +7 more
doaj   +1 more source

Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study [PDF]

, 2016
Purpose: The purpose of this study is to make a prospective evaluation of the effect of timolol 0.1% eye gel on short-term intraocular pressure (IOP) after an intravitreal injection (IVI) of ranibizumab. Participants and methods: One hundred and fifty
Allegrini, D., Dimastrogiovanni, A. F., Montesano, G., Pece, A.   +3 more
core   +3 more sources

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

Journal of Diabetes Investigation, EarlyView.
Combining oral sodium‐glucose cotransporter 2 inhibitors with reduced intravitreal injections of anti‐vascular endothelial growth factor showed potential efficacy for mild diabetic macular edema. ABSTRACT Aims To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular
Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote   +6 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Ranibizumab For Diabetic Macular Edema Refractory To Multiple Prior Treatments [PDF]

, 2016
Purpose: Diabetic macular edema can be refractory to multiple treatment modalities. Although there have been anecdotal reports of ranibizumab showing efficacy when other modalities provided limited benefit, little has been published on treatment for ...
Ciulla, Lauren, Ciulla, Thomas A., Harris, Alon, Hussain, Rehan M., Sink, Bethany   +4 more
core   +2 more sources

Neovascular age‐related macular degeneration without drusen

Acta Ophthalmologica, Volume 104, Issue 3, Page e300-e311, May 2026.
Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks, Elon H. C. van Dijk, Husein Ghalayini, Somayeh Bazdar, WeiFeng Yu, Suzanne Yzer, José P. Martinez Ciriano, Reinier O. Schlingemann, Roselie M. H. Diederen, Camiel J. F. Boon   +9 more
wiley   +1 more source

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BMC Ophthalmology, 2018
Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann   +9 more
doaj   +1 more source

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited [PDF]

, 2017
BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of ...
Adam Turpcu, Gary C. Brown, Heidi B. Lieske, Melissa M. Brown, Yamina Rajput   +4 more
core   +1 more source

Synergistic inhibition of macular vascular permeability in diabetic edema: Ginsenoside Rg3 enhances ranibizumab efficacy by targeting angiopoietin‐like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 751-765, May 2026.
Molecular mechanism of synergistic antagonism of ANGPTL4 and VEGF by ginsenoside Rg3 combined with ranibizumab, regulating the NRP/RhoA pathway to inhibit macular edema. ABSTRACT Aims This study investigated the molecular mechanisms by which ginsenoside Rg3 combined with ranibizumab alleviates diabetic macular edema (DME), focusing on antagonizing ...
Jiexin Yu, Xingyu Li, Yanli Liu
wiley   +1 more source